Supplemental Fig 1. An overview of study design. The recommended doses regimen is 160 mg at the first administration and then 80 mg at week 2, 4, 6, 8,10, and 12, followed by monthly maintenance dosin
Objective: The goal of this prospective observational present study was to identify adverse events (AEs) related to the use of intravenous access sites for infective endocarditis (IE) treatment in a t